XTL Biopharma (XTLB) Reports Breakeven Q2 Loss

XTL Biopharma (NASDAQ: XTLB) reported Q2 loss of $0.00, versus $0.00 reported last year.

Following XTL's registered direct offering in April, 2015, XTL had US$4.8 million in cash and cash equivalents as of June 30, 2015.

For earnings history and earnings-related data on XTL Biopharma (XTLB) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy